FDA grants Advancement Therapy Designation to esketamine for MDD, impending

suicide risk Janssen recently revealed that the FDA granted a Development Treatment Classification for esketamine, a non-competitive and subtype non-selective activity-dependent N-methyl-D-aspartate receptor antagonist, for major depressive disorder and impending risk for …

See all stories on this topic Vraylar ineffective as adjunct therapy for treatment-resistant MDD Allergan and Gedeon Richter recently launched findings that indicated inefficacy of flexible doses of Vraylar as adjunctive treatment for treatment-resistant major depressive condition. To evaluate effectiveness of flexible doses of Vraylar (cariprazine, Allergan …

See all stories on this topic Royal Australian and New Zealand College of Psychiatrists medical practice standards for mood disorders.Author info:(1)Discipline of Psychiatry, Kolling Institute, Sydney Medical School, University of Sydney, Sydney, NSW, Australia CADE Center, Department of Psychiatry, Royal North Coast Health center, St Leonards, NSW, Australia gin.malhi@sydney.edu.au.

See all stories on this subject Suicide more common in individuals with high systemic inflammation People with increased levels of swelling were 4 times more likely to complete suicide, compared with those with lower levels. “In psychiatric patients, inflammation is positively associated with the intensity of self-reported suicidal …

See all stories on this subject Patients and Therapists in the Context of Culture: An Expedition of the Borderland In between Sociology, Medication, and Psychiatry Key Made in U.S.A Origin Disclaimer: For particular items sold by Walmart on Walmart.com, the displayed native land information may not be accurate or consistent with producer details. For updated, accurate native land information, it is … See all stories on this subject